Details of the Drug Combinations

General Information of This Drug (ID: DMBZ27L)

Drug Name

Favipiravir DMBZ27L

Synonyms

AIDS121660; Favipiravir (JAN/INN); 3-bromo-5-hydroxy-4-methyl-2,6-dinitro-benzoic Acid; T705

Indication

Disease Entry	ICD 11	Status	REF
Influenza virus infection	1E30-1E32	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Favipiravir + Hydroxychloroquine	DC96P2Z	Hydroxychloroquine	COVID-19	[3]
Remdesivir + Favipiravir	DCEI7Q7	Remdesivir	Complication of Medical Care	[4]
Nitazoxanide + Favipiravir	DCP4GGF	Nitazoxanide	Covid19	[5]
Favipiravir + Azithromycin	DCRBMF4	Azithromycin	Infectious Disease	[6]
Favipiravir + Darunavir	DCJ0NU2	Darunavir	Coronavirus Disease 2019 (COVID-19)	[7]
Favipiravir + Lopinavir	DC0JRWJ	Lopinavir	Coronavirus Disease 2019 (COVID-19)	[7]
Remdesivir + Favipiravir	DCHWSKP	Remdesivir	Covid19	[8]
Favipiravir + Hydroxychloroquine	DCOG67U	Hydroxychloroquine	COVID-19	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DrugCom(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
3	ClinicalTrials.gov (NCT04376814) Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
4	ClinicalTrials.gov (NCT04727775) Antiviral Drugs on the Treatment of SARS-CoV-2
5	ClinicalTrials.gov (NCT04918927) Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
6	ClinicalTrials.gov (NCT04613271) Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
7	ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial
8	ClinicalTrials.gov (NCT04694612) Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
9	ClinicalTrials.gov (NCT04359615) Favipiravir in Hospitalized COVID-19 Patients